Esperion Therapeutics (ESPR) FCF Margin (2019 - 2026)
Esperion Therapeutics (ESPR) posted FCF Margin of 34.84% for Q1 2026, down 230.27% on a QoQ basis from 26.75% in Q4 2025, and down 3.0% year-over-year from 35.92% in Q1 2025.
Esperion Therapeutics (ESPR) FCF Margin (2019 - 2026) Analysis & Trends
Esperion Therapeutics' FCF Margin history runs 8 years deep, the most recent figure standing at 34.84% for Q1 2026.
- Quarterly FCF Margin fell 3.0% year-over-year to 34.84% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.44% (up 3422.0% YoY) and the FY2025 annual result came in at 3.29%, up 392.0% from the prior year.
- FCF Margin was 34.84% for Q1 2026 at Esperion Therapeutics, down from 26.75% in the prior quarter.
- Across five years, FCF Margin topped out at 39.03% in Q1 2024 and bottomed at 268.2% in Q2 2022.
- A 5-year average of 93.76% and a median of 56.89% in 2023 frame the typical range for FCF Margin.
- Peak annual rise in FCF Margin reached 90942 bps in 2022, while the deepest fall reached 15048 bps in 2022.
- Esperion Therapeutics' FCF Margin stood at 225.7% in 2022, then soared by 49 bps to 114.9% in 2023, then soared by 56 bps to 50.57% in 2024, then surged by 153 bps to 26.75% in 2025, then slumped by 230 bps to 34.84% in 2026.
- Business Quant data shows ESPR's FCF Margin at 34.84% in Q1 2026, 26.75% in Q4 2025, and 4.91% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -5.22% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 12.86% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -5.35% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 46.54% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 9.93% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 17.73% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.77% |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | -34.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.84% |
| Dec 31, 2025 | 26.75% |
| Sep 30, 2025 | -4.91% |
| Jun 30, 2025 | -38.14% |
| Mar 31, 2025 | -34.81% |
| Dec 31, 2024 | -50.57% |
| Sep 30, 2024 | -68.71% |
| Jun 30, 2024 | -9.89% |
| Mar 31, 2024 | 39.03% |
| Dec 31, 2023 | -114.90% |
| Sep 30, 2023 | -56.89% |
| Jun 30, 2023 | -95.98% |
| Mar 31, 2023 | -223.42% |
| Dec 31, 2022 | -225.70% |
| Sep 30, 2022 | -225.67% |
| Jun 30, 2022 | -268.20% |
| Mar 31, 2022 | -207.00% |
| Dec 31, 2021 | -374.69% |
| Sep 30, 2021 | -480.04% |
| Jun 30, 2021 | -117.73% |